FindTrial
Sign In

Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases

To study the levels of cytokines and pentraxin 3 levels in women with unexplained recurrent pregnancy loss and the effect of oral micronized progesterone therapy on cytokine and pentraxin 3 levels and its relation to the pregnancy outcome.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/09/007278
Enrollment
90
Registered
2016-09-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- pregnant patients with history of recurrent abortions and pregnant patients without recurrent aBORTIONS

Interventions

Intervention1: oral micronized progesterone: 30 females with RPL who were supplemented with oral micronized progesterone 200 mg BD till 16 weeks of pregnancy and 30 cases with RPL to whom no progest

Sponsors

All India Institute of Medical Sciences new delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Pregnant females at 21â??40 years of age; 2) Euthyroid state with normal thyroid function tests 3) All women who had two or more than two consecutive miscarriages of unknown cause

Exclusion criteria

Exclusion criteria: Women with a history of repeated miscarriage of known cause.

Design outcomes

Primary

MeasureTime frame
levels of cytokines in peripheral blood in women with RPL, effect of oral micronized progesterone on the cytokines and pentraxin 3 levels, effect of oral micronized progesterone on the pregnancy outcome in women with recurrent pregnancy loss, effect of oral micronized progesterone on the pregnancy outcome in relation to the cytokine levelsTimepoint: recruitment, 16 weeks, post delivery, post abortion—

Secondary

MeasureTime frame
levels of cytokine in peripheral blood in normal pregnancy, perinatal outcome , occurrence of obstetric complications like ICP, pre eclampsiaTimepoint: recruitment, 16 weeks, post delivery—

Countries

India

Contacts

Public Contactdr nutan agarwal

All India Institute of Medical Sciences, new Delhi

stuti.aiims@gmail.com8447555737

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 9, 2026